3/1/2022

speaker
Operator
Conference Operator

Good afternoon, and thank you for joining us today for Neoleucine Therapeutics Conference Call. At this time, all participants are in listen-only mode. Following the conclusion of the prepared remarks, we will conduct a question-and-answer session, and instructions will follow at that time. As a reminder, today's conference call is being recorded. I would now like to turn the call over to Julie Rathbun, Communications for Neoleucine Therapeutics. Julie, please go ahead.

speaker
Julie Rathbun
Communications, Neoleucine Therapeutics

Thank you. Good afternoon and welcome to the Neolucan Therapeutics year-end 2021 conference call. Joining me on the call today from Neolucan are Jonathan Drachman, CEO, Priti Patel, CMO, and Sean Smith, Vice President, Finance. Today's call is being recorded. It will be available for replay on the investor relations section of the Neolucan website approximately two hours after the call for at least 30 days. Before we start, I'd like to remind you that today's call will include forward-looking statements based on current expectations. Such statements represent management's judgments, intentions, beliefs, and expectations about future events, strategies, product candidates, and operating plans. All forward-looking statements included in this presentation are made as of today and involve assumptions, risks, and uncertainties, and actual results could differ materially from those anticipated in the forward-looking statements. Neolucan undertakes no obligation to update or revise any forward-looking statements. Please refer to the company's filings with the SEC, which are available from the SEC or on the Neolucan website, for information concerning the risk factors that could affect the company. I'd now like to turn the call over to Jonathan Drachman.

speaker
Jonathan Drachman
Chief Executive Officer

Jonathan Drachman Thank you, Julie, and good afternoon. I'd like to begin with a few recent transitions at Neolucan. First, I'd like to take a moment to acknowledge that Bob Ho will be leaving Neolucan after two years as our CFO to pursue another opportunity. He has built a strong finance department in his time with us and leaves us with an excellent team that will be led by Sean Smith, who is joining me on the call today. Sean has been with Neolucan since 2019 as our controller and will now lead the finance team and be our principal accounting officer until we appoint a new CFO. I'm very pleased to announce that we also have a new member of our board of directors, Rohan Palakar, who is currently the CEO of 89Bio. Rohan has decades of experience in biotechnology in both small and large companies and has held key leadership positions at J&J and Medivation before becoming CEO of Avenir and subsequently 89Bio. I look forward to working with Rohan on the board. Rohan will be replacing Rusty Williams, who will be stepping off the board after three years. Rusty has been a terrific board member, and we have benefited greatly from his wisdom and experience. And now I'd like to recap our progress in 2021 and look ahead to milestones expected during 2022. As a reminder, Neoleucin was founded at the end of 2018, went public in August of 2019 through a merger. We submitted our first IND at the end of 2020 and began a Phase I clinical trial in May of 2021. During our three-year history, Neoleucin has built a state-of-the-art computational and protein engineering research organization. The science underlying our technology has been published in the prestigious journals and we have assembled a talented team of more than 90 scientists, clinical developers, and biotech professionals to advance our science and develop novel therapies to help patients with serious medical illnesses. Today I'd like to discuss our progress with the first in human phase one clinical trial of NL201, our plans for further development of this program, and our early stage pipeline that we are advancing toward potential future clinical evaluation. 2021 was a busy year for Neoleukin. For starters, we added several key leaders to our executive team. In May, Dr. Priti Patel joined us as chief medical officer. Priti previously served as vice president, head of hematology clinical development at AstraZeneca and brings extensive experience in clinical development strategy and trial execution of investigational therapeutics with a specific expertise in oncology and hematologic malignancies. And last fall, Bill Arthur joined us as Vice President and Head of Research. Bill was previously at CGEN, where he served most recently as Senior Director and Head of Cancer Biology, and was previously at Merck and Rosetta in Pharmatics, leading the discovery of oncology targets, predictive biomarkers, and synergistic drug combinations. Bill is a skilled research leader who has guided research efforts on therapeutic candidates novel platform technologies. Both Preeti and Bill are great additions to our Neolucan team and are making significant impacts, leading our clinical and research efforts. In May of last year, we treated our first patient in a phase one clinical trial for NL201, officially making the transition to become a clinical stage company. We also moved into our new headquarters in Seattle with expanded lab and office space for our team. While the COVID pandemic has impacted our pipeline development, we now have the space and scientific expertise to make rapid progress. Although our rate of growth slowed somewhat during 2021, we finished the year with more than 90 full-time employees. And finally, in the second half of 2021, we presented preclinical data at multiple scientific conferences on topics ranging from NL201 and its effects on the tumor microenvironment to initial data about a novel IL-2, IL-15 inhibitor molecule. Looking forward, we expect a number of upcoming milestones in 2022. First, we expect to report in the second half of the year. We believe this will be the first data of a fully de novo protein in patients. Next, we plan to initiate a combination of NL201 and pembrolizumab in patients with advanced solid tumors. In addition, we plan to use information obtained from our solid tumor trial as well as preclinical data to begin evaluation of NL201 in hematologic malignancies. And finally, we anticipate providing further information on progress with the research pipeline. And now, turning to our clinical program, NL201. NL201 is a highly potent de novo protein that stimulates both the IL-2 and IL-15 receptors. NL201 was designed using computational methods evolution and extensive testing in the laboratory. It is thermodynamically hyperstable, more potent than native IL-2, and preferentially stimulates naive CD8 T cells and NK cells versus immunosuppressive T regulatory cells at low concentrations. Because the portion of the protein scaffold that normally interacts with the alpha subunit, also known as CD25, has been completely replaced, there is no residual or potential bias towards Tregs and no other high affinity sites that need to be saturated in order to activate potential cancer-fighting immune cells. I will now ask Preeti to talk about our clinical plans. Preeti?

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-